| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ef1a63d62269b5b64f99ee8720351481 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-2013 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-20 |
| filingDate |
1987-04-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c50e46f1f0be12308eaafdd75c409db2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_64cb258cd67d759d31da6b4dacca4b1e |
| publicationDate |
1987-10-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
GB-2189393-A |
| titleOfInvention |
Combination therapy using interleukin-2 and glucocorticoid |
| abstract |
Anti-tumor activity in mammals can be combatted by administering to the mammalian host a synergistically effective amount of human IL-2 and one or more glucocorticoids in combination. The composition of IL-2 and glucocorticoid(s) may be prepared in vitro or administered separately to the host. The composition is useful for treating such cancers as sarcoma. The glucocorticoid is preferably dexamethasone. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10898576-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5089261-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-8909062-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1939216-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108778316-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108778316-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3431096-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1939216-A4 |
| priorityDate |
1986-04-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |